Expertise in
11
conditions

Alain Dupuy

CHU Rennes
Rennes, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
CHU Rennes
Rennes, FR 

Overview

Alain Dupuy practices practicing medicine in Rennes, France.

Mr. Dupuy is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Melanoma, Perniosis, Frostbite, and Pemphigus Foliaceus.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

CHU Rennes
Rennes, France
Other Locations
C Sanofi R&D, Vitry-sur-seine, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Other
Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
Multicentre, Cross-over, PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter as an add-on Therapy, Coupled With Oral Vitamin D Supplementation vs. Placebo in a Randomised, Parallel-group Trial
Multicentre, Cross-over, PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter as an add-on Therapy, Coupled With Oral Vitamin D Supplementation vs. Placebo in a Randomised, Parallel-group Trial
Enrollment Status: Completed
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: Cholecalciferol
Study Phase: Phase 2
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Enrollment Status: Completed
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: Imiquimod Cream+Surgery, Surgery
Study Phase: Phase 3
RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE)
RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE)
Enrollment Status: Completed
Publish Date: May 29, 2018
Intervention Type: Drug
Study Phase: Phase 3
Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria
Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria
Enrollment Status: Completed
Publish Date: September 20, 2017
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

144 Total Publications

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.
Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.
Journal: JAMA dermatology
Published: September 03, 2025

Frequently Asked Questions about Alain Dupuy

Is Alain Dupuy a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alain Dupuy is classified as an Advanced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alain Dupuy participate in research or clinical trials?

Yes. Alain Dupuy has published 144 articles and abstracts on conditions like Melanoma. You can view a list of Alain Dupuy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dupuy's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 44 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile